Gain-of-Function Variant <i>TRPC6 A404V</i> Is Associated With Doxorubicin-Related Cardiomyopathy
The <i>TRPC6 A404V</i> is a gain-of-function variant that exhibits enhanced activity in the presence of doxorubicin. Therefore, the <i>TRPC6 A404V</i> variant represents a risk factor for anthracycline-induced cardiotoxicity in patients with cancer.
Authors
- XIAOJING SUN
- Joseph Swaroop Reddy
- R X Wang
- Hon-Chi Lee
- Ying Wu
- Tong Lu
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Wuxi People's Hospital (CN)
Publication Details
- Journal
- Circulation Genomic and Precision Medicine
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1161/circgen.125.005334
- Primary Topic
- Ion Channels and Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00